Topic: initial public offering
Little more than a week after investors hailed Lilly’s plan to spin off Elanco, it filed IPO plans showing the animal health unit has some growing pains.
Shire nixed Takeda's $60 billion-plus buyout offer, Hanmi ditched lung cancer hopeful olmutinib, Grail is looking for $1 billion before Hong Kong IPO.
Takeda weighs a $52 billion Shire bid, WuXi gets approval for a $900M-plus Shanghai IPO, Aslan aims to raise $86 million through an IPO on Nasdaq.
Shionogi’s flu drug won Japanese approval; Sun Pharma's Halol plant was cited by the FDA; EpimAb hired a top Novartis researcher as CMO; plus more.
J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge discounts.
WuXi AppTec started IPO prep for core drug R&D, Purdue and Shionogi won approval for a new constipation med, and an Indian CRO's meds were halted by EMA.
China Resources Pharmaceutical Group will kick off its initial public offering in Hong Kong in the next few days, hoping to raise up to $2 billion for investment and expansion.
Samsung BioLogics has always said it will become the big deal in large-molecule manufacturing. Now it intends to back that boast up with an IPO that could value the company at more than $8 billion while filling its pockets with $2 billion in cash.